UnitedHealth price target lowered to $550 from $590 at UBS

UBS analyst Kevin Caliendo lowered the firm’s price target on UnitedHealth to $550 from $590 and keeps a Neutral rating on the shares. UnitedHealth’s Q4 results were broadly positive, but thinks shares will remain range-bound until there is more clarity on the final RADV ruling and the advanced rate notice and how they impact Medicare Advantage, Caliendo tells investors in a research note.